ALMS

3.9608.55%
CP

C. Patrick Machado

Independent Director

Mr. C. Patrick Machado, also known as Pat, Pharm.D., J.D., is Director of Avenzo Therapeutics, Inc. from November 2024. Mr. Machado is an Independent Chairman of Prota Therapeutics Pty Ltd since June 24, 2024. Mr. Machado serves as an Independent Director of Alumis Inc. since June 2024. He is Independent Director at Arcus Biosciences, Inc. since December 2019. He served as Independent Director at Turnstone Biologics Corp. since August 2018 until April 15, 2024. He co-founded Medivation, Inc. in 2003. He was Independent Director of Roivant Sciences Ltd. since October 2016 until July 14, 2022. Mr. Machado had been a Director of Turning Point Therapeutics, Inc. since May 14, 2019 until August 15, 2022. He served as the Chief Financial Officer, Principal Accounting Officer and Chief Business Officer at Medivation, Inc. from August 2003 to April 18, 2014. He served as an Interim Chief Business and Financial Officer at Medivation, Inc., since November 2013. He served as Chief Financial Officer and Senior Vice President of Orion Acquisition Corp. II since December 17, 2004 and also served as its Principal Accounting Officer. He served as the Chief Financial Officer at Medivation, Inc. from December 17, 2004 to November 2013 and served as its Chief Business Officer from December 2009 to November 2013. He served as Senior Vice President of Medivation, Inc. since December 17, 2004 and also served as its Secretary until April 2013. He served as Chief Financial Officer and Senior Vice President of Medivation, Inc., since September 2003. From 1998 to 2001, Mr. Machado served at Product Health, Inc. where he served as its Vice President, Chief Financial Officer and General Counsel from 1998 to 2000 and Senior Vice President and Chief Financial Officer from 2000 to 2001. From 2001 to 2002, he served as a Consultant to Cytyc Corporation to assist with transitional matters related to Cytyc Corporations acquisition of Product Health, Inc. He was an Independent Director at SCYNEXIS, Inc. from September 24, 2015 to April 2019. He was Independent Director at Chimerix, Inc. since June 2014 until June 20, 2024. He had been an Independent Chairman of the Board of Adverum Biotechnologies, Inc. since May 1, 2019 until December 9, 2025 and was its Director since March 14, 2017 until December 9, 2025. He has experience growing biopharmaceutical organizations from development through commercialization. He serves as an Independent Director at Xenon Pharmaceuticals Inc. since November 2020. He served as an Independent Director of ACELYRIN, Inc. since May 2021 until May 2025. He served on the Board of Turnstone Biologics from August 2018 to April 2024. He served as an Outside Director of Inotek Pharmaceuticals Corporation since August 18, 2016. He served as a Director of Endocyte Inc. from February 2018 to December 2018, Therachon and Axovant Sciences Ltd from June 2017 to February 2018. Earlier, he served as Senior Vice President, finance and business development, Chief Financial Officer and General Counsel of Pro-Duct Health, Inc., a medical device company. He served as a Director at Pro-Duct, Inc., since April 18, 2014 until September 28, 2016. Earlier in his career, Mr. Machado served as chief legal counsel to the Chiron Technologies business unit at Chiron Corporation from 1996 until 1998 and led the transaction teams for all substantial Chiron Technologies collaborations. He served as a Director of Medivation since September 2003. Mr. Machado previously served on the board of directors of Sio Gene Therapies Inc. (f.k.a. Axovant Sciences, Inc.) (Nasdaq: SIOX) from June 2017 until February 2018, Rocket Pharmaceuticals, Inc. (f.k.a. Inotek Pharmaceuticals Corporation) (Nasdaq: RCKT) from August 2016 until January 2018, Principia Biopharma Inc. from June 2019 until its acquisition by Sanofi S.A. in September 2020. Earlier in his career, Mr. Machado worked for Morrison & Foerster LLP, an international law firm and for the Massachusetts Supreme Judicial Court from 1990 until 1996. Mr. Machado received a J.D. from Harvard Law School from 1986 to 1989 and a B.A. and B.S. in German and Economics, respectively, from Santa Clara University from 1982 to 1986.

公司职务